Figure 1. Flowchart for the OSA group. T1: Before treatment with MAD; T2: After treatment with MAD.

Figure 2. Difference in daytime sleepiness between the OSA group and the control group before MAD treatment (T1) and before (T1) and after (T2) MAD treatment in the OSA group. Significant differences are shown with lines and p values.

Figure 3. Differences in quality of life between the OSA group and the control group before (T1) MAD treatment. Significant differences are shown with lines and p values.

Figure 4. Differences in quality of life for the OSA group before (T1) and after (T2) MAD treatment. Significant differences are shown with lines and p values.

Table 1. Differences in daytime sleepiness and quality of life between the OSA group and the control group before MAD treatment. The estimates are shown with 95% confidence intervals, p-values and coefficients of determination (r2). Adjusted for sex and age.

Table 1. Differences in daytime sleepiness and quality of life between the OSA group and the control group before MAD treatment. The estimates are shown with 95% confidence intervals, p-values and coefficients of determination (r2). Adjusted for sex and age.

VariablesDifference OSA vs. Control (95% Confidence Interval)r2 (Coefficient of Determination)p-ValueDaytime sleepiness ESS2.36 (0.56−4.15)0.160.0110 *Quality of life Physical functioning−7.67 (−14.23–(−1.12))0.100.0226 *Role limitations (physical)−16.32 (33.58–0.94)0.060.06Role limitations (emotional)−14.57 (−26.46–(−2.68))0.130.0173 *Energy/vitality−24.51 (−34.44–(−14.58))0.33<0.0001 ****Mental health−11.72 (−19.31–(−4.13))0.220.0031 **Social functioning−13.72 (−24.28–(−3.15))0.190.0119 *Pain−8.08 (−20.12–3.96)0.040.18General health perceptions−16.29 (−24.54–(−8.04))0.250.0002 ***

Table 2. Differences in daytime sleepiness and quality of life in the OSA group before (T1) and after (T2) MAD treatment. The estimates are shown with 95% confidence intervals, p-values and correlation coefficients (r). Adjusted for sex and age.

Table 2. Differences in daytime sleepiness and quality of life in the OSA group before (T1) and after (T2) MAD treatment. The estimates are shown with 95% confidence intervals, p-values and correlation coefficients (r). Adjusted for sex and age.

VariablesDifference T2 vs. T1 (95% Confidence Interval)r (Correlation Coefficient)p-ValueDaytime sleepiness ESS−2.25 (−3.52−(−0.98))0.850.0018 *Quality of life Physical functioning−2.19 (−6.75–2.37)0.840.32Role limitations (physical)7.81 (−11.47–27.10)0.560.40Role limitations (emotional)6.26 (−11.17–23.69)0.560.46Energy/vitality18.13 (6.87–28.38)0.470.0037 *Mental health4.75 (−7.97–17.47)0.040.44Social functioning10.84 (−0.17–22.05)0.540.05Pain7.50 (−7.27–22.27)0.300.30General health perceptions4.38 (−1.45–10.20)0.850.13